Epizyme, Inc (EPZM) saw its loss widen to $32.52 million, or $0.56 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $22.88 million, or $0.41 a share. The company has not recorded any revenues for the current quarter. However, it has reported a revenue of $0.47 million for the previous year period.
Operating loss for the quarter was $32.96 million, compared with an operating loss of $23.11 million in the previous year period.
“Already in 2017, we have made progress in our novel epigenetic pipeline, led by tazemetostat,” stated Robert Bazemore, president and chief executive officer. “We have continued to advance tazemetostat in multiple clinical trials in a range of solid tumors and hematological malignancies, and as both a monotherapy and in combination with other anti-cancer agents. We look forward to reporting interim data from our Phase 2 study in molecularly defined solid tumors in our conference call next week and from our Phase 2 study in relapsed or refractory FL and DLBCL in June.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]